<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.1038/s41598-020-57843-9 : Article Potent inhibition of HIV replication in" exact="primary" post="human cells by novel synthetic polyketides inspired by Aureothin"/>
 <result pre="Medicine, University of Michigan, [4], 0000 0004 0483 2525grid.4567.0Research Unit" exact="Protein" post="Science, Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit"/>
 <result pre="license, visit http://creativecommons.org/licenses/by/4.0/. Abstract Overcoming the global health threat of" exact="HIV infection" post="requires continuous pipelines of novel drug candidates. We identified"/>
 <result pre="visit http://creativecommons.org/licenses/by/4.0/. Abstract Overcoming the global health threat of HIV" exact="infection" post="requires continuous pipelines of novel drug candidates. We identified"/>
 <result pre="hits by anti-HIV screening of an extensive natural compound collection." exact="Total" post="synthesis of a structurally diverse group of Aureothin-derivatives successfully"/>
 <result pre="RNAs that encode the structural components of virions and include" exact="viral" post="genomic RNAs. Thus, the mode-of-action displayed by compound #7"/>
 <result pre="that compound #7 does not affect global protein expression in" exact="primary" post="blood cells and may modulate cellular pathways linked to"/>
 <result pre="primary blood cells and may modulate cellular pathways linked to" exact="HIV infection." post="Compound #7 inhibited multiple HIV genotypes, including HIV-type 1"/>
 <result pre="and holds promise for further drug development. Subject terms HIV" exact="infections" post="Phenotypic screening Funding Helmholtz Zentrum München - Deutsches Forschungszentrum"/>
 <result pre="Introduction With over 37 million individuals globally living with HIV," exact="HIV infection" post="represents a serious public health threat. HIV treatment was"/>
 <result pre="With over 37 million individuals globally living with HIV, HIV" exact="infection" post="represents a serious public health threat. HIV treatment was"/>
 <result pre="countries exceeded 10%, as well as prevalence of drug resistance" exact="acquired" post="during cART treatment (4–28%). Therefore, a major target of"/>
 <result pre="a major target of the global action plan for overcoming" exact="HIV/AIDS" post="is the intensification of research for the development of"/>
 <result pre="HIV inhibitory activity of prototypical compound #7 was apparent in" exact="primary" post="HIV-target cells, directed against multiple HIV genotypes, including clinical"/>
 <result pre="and to expand options for anti-HIV treatment. Results Identification of" exact="bacterial" post="γ-pyrone polyketides (Aureothin/Neoaureothin) as potent HIV inhibitors To identify"/>
 <result pre="compounds: Anti-HIV activity was evaluated by determining compound effects on" exact="infectious" post="virus production by LC5-RIC cells which are highly susceptible"/>
 <result pre="the assay). Subsequently, supernatants of these cultures were transferred to" exact="secondary" post="plates with uninfected LC5-RIC cells. The fluorescent signal of"/>
 <result pre="LC5-RIC cells. The fluorescent signal of the cultures in the" exact="secondary" post="plates served as a measure of compound effects on"/>
 <result pre="secondary plates served as a measure of compound effects on" exact="infectious" post="virus production. The polyketide Aureothin and the related molecule"/>
 <result pre="very potent anti-HIV activity, which was comparable or only moderately" exact="lower" post="than that of several clinical drugs assayed in parallel"/>
 <result pre="Aureothin analogues. Table 1 Inhibitory activities of synthetic Aureothin-derivatives against" exact="HIV infection" post="of human primary blood-derived mononuclear cells (PBMCs). Shown are"/>
 <result pre="analogues. Table 1 Inhibitory activities of synthetic Aureothin-derivatives against HIV" exact="infection" post="of human primary blood-derived mononuclear cells (PBMCs). Shown are"/>
 <result pre="Inhibitory activities of synthetic Aureothin-derivatives against HIV infection of human" exact="primary" post="blood-derived mononuclear cells (PBMCs). Shown are the molecular structures"/>
 <result pre="and were reacted with the boronic ester of the key" exact="intermediate" post="γ-pyrone-furanone (compound #2)14,15, followed by Br-methyl conversion with Zn(CH3)2"/>
 <result pre="anti-HIV activities of all Aureothin derivatives was then repeated using" exact="primary" post="human target cells for HIV, i.e. peripheral blood mononuclear"/>
 <result pre="then repeated using primary human target cells for HIV, i.e." exact="peripheral" post="blood mononuclear cells (PBMC), in at least three independent"/>
 <result pre="different donors as described in Materials and Methods (Inhibition of" exact="infection" post="assays). Compounds (#3, #6, #7, #12, #13, and #21)"/>
 <result pre="1). However, determination of concentrations required for 90% inhibition of" exact="HIV infection" post="of PBMC revealed an IC90 value comparable to Aureothin"/>
 <result pre="However, determination of concentrations required for 90% inhibition of HIV" exact="infection" post="of PBMC revealed an IC90 value comparable to Aureothin"/>
 <result pre="for compound #7. The other compounds in this collection showed" exact="lower" post="anti-HIV activities than Aureothin. As expected, a truncated compound"/>
 <result pre="nature of the para-substituent in the aryl-moiety for inhibition of" exact="HIV infection." post="Neoaureothin was previously reported to be photolabile, showing light-induced"/>
 <result pre="dark. Anti-HIV activity was measured by quantifying the amounts of" exact="infectious" post="virus produced by HIV-1LAI exposed LC5-RIC cells treated with"/>
 <result pre="regulatory elements of HIV expression and is activated by early" exact="viral" post="gene expression during HIV infection6. Use of LC5-RIC cells"/>
 <result pre="compound treatment on expression of the DsRed1 reporter gene and" exact="infectious" post="virus production in the same cultures. As reference compound,"/>
 <result pre="comparing effects of compound treatment on reporter gene expression and" exact="infectious" post="virus production. As expected, treatment with Flavopiridol yielded both"/>
 <result pre="Flavopiridol yielded both very strong inhibition of DsRed1 expression and" exact="infectious" post="virus production. In contrast, compound #7 treatment displayed highly"/>
 <result pre="expression was not or poorly inhibited, compound #7 strongly blocked" exact="infectious" post="virus production. These results indicate that while compound #7"/>
 <result pre="while compound #7 treatment can have inhibitory effects on early" exact="viral" post="gene expression, this inhibitory effect is variable and is"/>
 <result pre="is variable and is thus not the major effect blocking" exact="infectious" post="virus production. Figure 2 Comparison of effects of compound"/>
 <result pre="compound #7 treatment on reporter gene expression and production of" exact="infectious" post="virus in LC5-RIC cultures. LC5-RIC cells contain a reporter"/>
 <result pre="cells contain a reporter gene that is activated by early" exact="viral" post="gene expression during HIV infection and encodes a red"/>
 <result pre="gene that is activated by early viral gene expression during" exact="HIV infection" post="and encodes a red fluorescent protein (DsRed1). Effects of"/>
 <result pre="that is activated by early viral gene expression during HIV" exact="infection" post="and encodes a red fluorescent protein (DsRed1). Effects of"/>
 <result pre="of compound treatment on reporter gene expression and production of" exact="infectious" post="virus were determined in LC5-RIC cultures exposed to virus"/>
 <result pre="LC5-RIC cultures exposed to virus inoculum in the presence or" exact="absence of" post="compounds for 48 h. Fluorescent signals of these primary cultures"/>
 <result pre="or absence of compounds for 48 h. Fluorescent signals of these" exact="primary" post="cultures were measured to determine effects on reporter gene"/>
 <result pre="measured to determine effects on reporter gene expression. Effects on" exact="infectious" post="virus production were determined by transferring aliquots of the"/>
 <result pre="production were determined by transferring aliquots of the supernatants of" exact="primary" post="cultures to uninfected LC5-RIC cells, and fluorescent signals determined"/>
 <result pre="cultures to uninfected LC5-RIC cells, and fluorescent signals determined in" exact="secondary" post="plates 72 h after transfer. Fluorescent signal intensities of compound-treated"/>
 <result pre="#7 treatment on levels of integrated proviral DNA and cellular" exact="viral" post="proteins and mRNAs in LC5-RIC cells, under conditions fully"/>
 <result pre="reference drugs was performed at concentrations yielding full inhibition of" exact="infectious" post="virus production (&amp;gt;2x IC90). Treatment with EFV or DTG"/>
 <result pre="not primarily block HIV replication by inhibiting provirus integration. The" exact="viral" post="Gag protein is the major structural protein of HIV"/>
 <result pre="replication cycle. During expression, multiple mRNAs are generated from a" exact="primary" post="transcript by alternative splicing20, forming three classes of HIV"/>
 <result pre="integration of proviruses, diminishing production of unspliced and singly spliced" exact="viral" post="transcripts, which are key transcripts for de novo virus"/>
 <result pre="both on a general level and in the context of" exact="HIV infection." post="We carried out semi-quantitative analysis of the proteomes of"/>
 <result pre="in compound treated, HIV-exposed samples was confirmed by quantification of" exact="infectious" post="virus levels in culture supernatants. The low proportion of"/>
 <result pre="pathway terms from the Canonical Pathways database were related to" exact="HIV infection" post="(Fig. 4; Supplementary Table S3). Figure 4 Summarised enrichment"/>
 <result pre="terms from the Canonical Pathways database were related to HIV" exact="infection" post="(Fig. 4; Supplementary Table S3). Figure 4 Summarised enrichment"/>
 <result pre="↓ down-regulated) or PBMC exposed to compound #7 in the" exact="absence of" post="HIV (also up- and down-regulated) were determined and shown"/>
 <result pre="analysis suggests good biocompatibility of compound #7 treatment with only" exact="limited" post="global effects on protein expression in PBMCs. Profiling these"/>
 <result pre="the outlier group O (HIV-1OMVP5180-91). Antiviral activities were evaluated in" exact="primary" post="human HIV-1 target cells, i.e. PBMCs. As shown in"/>
 <result pre="(a,b,c) and integrase inhibitors (d) resulted in synergistic inhibition of" exact="HIV infection." post="No synergisms were observed for combination of compound #7"/>
 <result pre="Synergistic effects of compound #7 and DTG combinations were somewhat" exact="lower" post="at ED75 than at ED90. Synergistic effects were not"/>
 <result pre="microorganisms, parasites and vermin and to inhibit proliferation of selected" exact="cancer" post="cell lines26–30. We identified the γ-pyrone polyketides Aureothin/Neoaureothin as"/>
 <result pre="of a natural compound library for HIV inhibitors. Only very" exact="limited" post="preliminary information supporting antiviral activity of Aureothin is available"/>
 <result pre="potentially toxic nitro group with more favourable substituents like fluorine." exact="Selective" post="introduction of fluorine residues has been used to improve"/>
 <result pre="replacing the nitro-group, was most effective in achieving&amp;gt;90% inhibition of" exact="HIV infection" post="in PBMCs (IC90 &amp;lt;45 nM). Substitutions by chlorine (compound #3,"/>
 <result pre="the nitro-group, was most effective in achieving&amp;gt;90% inhibition of HIV" exact="infection" post="in PBMCs (IC90 &amp;lt;45 nM). Substitutions by chlorine (compound #3,"/>
 <result pre="can be achieved by introduction of halogens and is not" exact="limited" post="to fluorine residues. Overall these results confirm that the"/>
 <result pre="show that compound #7 very strongly reduced levels of the" exact="viral" post="Gag polyprotein. Importantly, compound #7 treatment inhibited accumulation of"/>
 <result pre="cycle. 1, Attachment of virus to receptor; 2, Fusion of" exact="viral" post="and cellular membranes; 3, Uncoating and delivery of viral"/>
 <result pre="of viral and cellular membranes; 3, Uncoating and delivery of" exact="viral" post="RNA to cytoplasm; 4, Generation of the DNA copy"/>
 <result pre="RNA to cytoplasm; 4, Generation of the DNA copy of" exact="viral" post="genome by reverse transcription; 5, Nuclear import of viral"/>
 <result pre="of viral genome by reverse transcription; 5, Nuclear import of" exact="viral" post="DNA and integration into host cell genome; 6, Virus"/>
 <result pre="expression; 7, Assembly of Gag, Pol, Env proteins and unspliced" exact="viral" post="RNAs to virus particles; 8, Budding of immature virus"/>
 <result pre="compound #7 encode for Gag, Pol, Env proteins and included" exact="viral" post="RNAs packaged into new virions. Compound #7 treatment affected"/>
 <result pre="HIV mRNAs and their translation34–39 and involve numerous interactions of" exact="viral" post="components with cellular partners. We expect future studies dissecting"/>
 <result pre="of PBMCs (Supplementary Fig. S4), confirming that the inhibition of" exact="viral" post="protein expression is not a consequence of unspecific global"/>
 <result pre="identified various terms connected with the immune system and with" exact="viral" post="(including HIV) infection (Fig. 4). Several terms were enriched"/>
 <result pre="connected with the immune system and with viral (including HIV)" exact="infection" post="(Fig. 4). Several terms were enriched only in HIV-exposed"/>
 <result pre="of compound #7 on cellular processes specific for HIV-exposed human" exact="primary" post="blood cells awaits further elucidation, possibly by combining results"/>
 <result pre="cell-focused mode-of-action. In contrast, some compounds designed to interfere with" exact="viral" post="components show selective inhibition of individual HIV genotypes. For"/>
 <result pre="NIAID, NIH, from Dr. Keith Peden42) as described8. Isolation of" exact="primary" post="clinical HIV-isolates HIV-1MMVP899-87, HIV-1OMVP5180-91, HIV-1V13-03413B and HIV-2MVP10668-93 is described"/>
 <result pre="isolates were produced from HIV infected H9 cells as described8." exact="Infectious" post="titres of virus samples were determined by measuring the"/>
 <result pre="of virus samples were determined by measuring the Tissue Culture" exact="Infectious" post="Dose 50 (TCID50), using LC5-RIC HIV reporter cells. Briefly,"/>
 <result pre="LC5-RIC, the human T-lymphoma cell line H9 (ATCC®-Number HTB-176) and" exact="peripheral" post="blood mononuclear cells (PBMC) were cultured as described in6,8."/>
 <result pre="described in6,8. PBMCs were isolated from buffy-coats (received from the" exact="Blood" post="Donation Services of the Bavarian Red Cross GmbH) by"/>
 <result pre="was purchased from Biomol. All Aureothin derivatives were produced by" exact="total" post="synthesis by Bicoll Biotechnology Co. Ltd., mainly following the"/>
 <result pre="assays. Cell-based assays for characterization of antiviral activities Inhibition of" exact="infection" post="assays Anti-HIV activities of compounds were profiled in LC5-RIC"/>
 <result pre="and compounds (first step of the assay). Compound effects on" exact="infectious" post="virus production were determined by transferring aliquots of supernatants"/>
 <result pre="determined by transferring aliquots of supernatants of compound-treated cultures to" exact="secondary" post="plates and measurement of fluorescent signal intensities in secondary"/>
 <result pre="to secondary plates and measurement of fluorescent signal intensities in" exact="secondary" post="plates after 72 h (second step of the assay). Fluorescent"/>
 <result pre="of 0.5. To evaluate anti-HIV efficacies of test compounds in" exact="primary" post="human target cells, stimulated PBMCs were seeded in 96-well"/>
 <result pre="0.5) added to the PBMCs and cultures incubated for 48 h." exact="Infectious" post="virus production was quantified by transferring 35 µl of supernatant"/>
 <result pre="and their anti-HIV activity determined by measuring compound effects on" exact="infectious" post="virus production with the EASY-HIT assay. Relative photostability was"/>
 <result pre="compounds kept in the dark. Assays for quantification of cell-associated" exact="HIV infection" post="parameters Quantitative analysis of integrated copies of HIV proviral"/>
 <result pre="kept in the dark. Assays for quantification of cell-associated HIV" exact="infection" post="parameters Quantitative analysis of integrated copies of HIV proviral"/>
 <result pre="according to the manufacturer’s protocol. For cDNA synthesis, 1 µg of" exact="total" post="RNA was reverse transcribed by SuperScript II reverse transcriptase"/>
 <result pre="Gag-p24 and GAPDH was performed as described in48, using the" exact="primary" post="antibodies anti-hGAPDH (ThermoFisher Scientific) and anti-HIV-p24 (Calbiochem) as well"/>
 <result pre="anti-hGAPDH (ThermoFisher Scientific) and anti-HIV-p24 (Calbiochem) as well as the" exact="secondary" post="anti-mouse-peroxidase antibody (Jackson ImmunoResearch), all diluted 1:10,000. Bands were"/>
 <result pre="37 °C, 5% CO2. HIV inhibition was confirmed by quantifying" exact="infectious" post="virus production in LC5-RIC cells as described above. Protein"/>
 <result pre="quantifying infectious virus production in LC5-RIC cells as described above." exact="Protein" post="lysates were prepared from cells harvested, washed with PBS"/>
 <result pre="for 20 min at 4 °C, 16,000 g to clear protein lysates." exact="Protein" post="concentrations were determined by using the PierceTM BCA Protein"/>
 <result pre="lysates. Protein concentrations were determined by using the PierceTM BCA" exact="Protein" post="Assay Kit (ThermoFisher Scientific) according to manufacturer’s protocol. The"/>
 <result pre="J. Eberle, Max von Pettenkofer Institute, Munich, for generously providing" exact="primary" post="HIV-isolates. We thank Marcel Blindert for generation of the"/>
 <result pre="received consulting fees. References References 1.GhosnJTaiwoBSeedatSAutranBKatlamaCHivLancet201839268569710.1016/S0140-6736(18)31311-430049419 2.CohenMSet al.Prevention of HIV-1" exact="infection" post="with early antiretroviral therapyN. Engl. J. Med.201136549350510.1056/NEJMoa110524321767103 3.RodgerAlison JCambianoValentinaBruunTinaVernazzaPietroCollinsSimonDegenOlafCorbelliGiulio"/>
 <result pre="transmission through condomless sex in serodifferent gay couples with the" exact="HIV-positive" post="partner taking suppressive antiretroviral therapy (PARTNER): final results of"/>
 <result pre="of a multicentre, prospective, observational studyThe Lancet2019393101892428243810.1016/S0140-6736(19)30418-0 4.WHO. HIV Drug" exact="Resistance" post="Report 2017. Geneva, World Health Organization; Licence: CC BY-NC-SA"/>
 <result pre="activity of Cistus incanus extract against HIV and Filoviruses targets" exact="viral" post="envelope proteinsSci. Rep.201662039410.1038/srep2039426833261 9.NakataHet al.Activity against human immunodeficiency virus"/>
 <result pre="Filoviruses targets viral envelope proteinsSci. Rep.201662039410.1038/srep2039426833261 9.NakataHet al.Activity against human" exact="immunodeficiency" post="virus type 1, intracellular metabolism, and effects on human"/>
 <result pre="viral envelope proteinsSci. Rep.201662039410.1038/srep2039426833261 9.NakataHet al.Activity against human immunodeficiency virus" exact="type 1," post="intracellular metabolism, and effects on human DNA polymerases of"/>
 <result pre="on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosineAntimicrob. Agents Chemother.2007512701270810.1128/AAC.00277-0717548498 10.HazenRJet al.Anti-human" exact="immunodeficiency" post="virus type 1 activity of the nonnucleoside reverse transcriptase"/>
 <result pre="DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosineAntimicrob. Agents Chemother.2007512701270810.1128/AAC.00277-0717548498 10.HazenRJet al.Anti-human immunodeficiency virus" exact="type 1" post="activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in"/>
 <result pre="III. Predictions and extension to new substituentsEnviron. Toxicol. Chem.1989843143610.1002/etc.5620080509 14.JacobsenMFMosesJEAdlingtonRMBaldwinJEA" exact="short" post="total synthesis of aureothin and N-acetylaureothamineOrg. Lett.2005764164410.1021/ol047594l15704914 15.JacobsenMFMosesJEAdlingtonRMBaldwinJEThe biomimetic"/>
 <result pre="Predictions and extension to new substituentsEnviron. Toxicol. Chem.1989843143610.1002/etc.5620080509 14.JacobsenMFMosesJEAdlingtonRMBaldwinJEA short" exact="total" post="synthesis of aureothin and N-acetylaureothamineOrg. Lett.2005764164410.1021/ol047594l15704914 15.JacobsenMFMosesJEAdlingtonRMBaldwinJEThe biomimetic synthesis"/>
 <result pre="Lett.2005764164410.1021/ol047594l15704914 15.JacobsenMFMosesJEAdlingtonRMBaldwinJEThe biomimetic synthesis of SNF4435C and SNF4435D, and the" exact="total" post="synthesis of the polyene metabolites aureothin, N-acetyl-aureothamine and spectinabilinTetrahedron2006621675168910.1016/j.tet.2005.11.058."/>
 <result pre="toxic substance of Streptomyces thioluteus producing aureothricinJ. Antibiot.1953613713813096448 27.HenrotMJeanAPeixotoPAMaddalunoJDe PaolisMFlexible" exact="Total" post="Synthesis of (+/−)-Aureothin, a Potent Antiproliferative AgentJ. Org. Chem.2016815190520110.1021/acs.joc.6b0087827213834"/>
 <result pre="Synthesis of (+/−)-Aureothin, a Potent Antiproliferative AgentJ. Org. Chem.2016815190520110.1021/acs.joc.6b0087827213834 28.WerneburgMHertweckCChemoenzymatic" exact="total" post="synthesis of the antiproliferative polyketide (+)-(R)-aureothinChembiochem200892064206610.1002/cbic.20080030118690656 29.WerneburgMet al.Exploiting enzymatic"/>
 <result pre="expression by SR proteinsBiochem. Soc. Trans.2016441417142510.1042/BST2016011327911724 40.BorregoPet al.Baseline susceptibility of" exact="primary" post="HIV-2 to entry inhibitorsAntivir. Ther.20121756557010.3851/IMP199622293827 41.WitvrouwMet al.Activity of non-nucleoside"/>
 <result pre="properties on passage in tissue culture of viruses derived from" exact="infectious" post="molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELIVirology199118566167210.1016/0042-6822(91)90537-L1683726 43.GurtlerLGet al.A"/>
 <result pre="HIV-1LAI, HIV-1MAL, and HIV-1ELIVirology199118566167210.1016/0042-6822(91)90537-L1683726 43.GurtlerLGet al.A new subtype of human" exact="immunodeficiency" post="virus type 1 (MVP-5180) from CameroonJ. Virol.1994681581158510.1128/JVI.68.3.1581-1585.19948107219 44.ReedLJMA Simple"/>
 <result pre="and HIV-1ELIVirology199118566167210.1016/0042-6822(91)90537-L1683726 43.GurtlerLGet al.A new subtype of human immunodeficiency virus" exact="type 1" post="(MVP-5180) from CameroonJ. Virol.1994681581158510.1128/JVI.68.3.1581-1585.19948107219 44.ReedLJMA Simple Method of Estimating"/>
 <result pre="human immunodeficiency virus type 1 (MVP-5180) from CameroonJ. Virol.1994681581158510.1128/JVI.68.3.1581-1585.19948107219 44.ReedLJMA" exact="Simple" post="Method of Estimating Fifty Percent EndpointsAm. J. Hyg.193827493497 45.Fuss,"/>
 <result pre="D. &amp;amp; Zola, H. Isolation of whole mononuclear cells from" exact="peripheral" post="blood and cord blood. Curr Protoc Immunol Chapter 7,"/>
 <result pre="Chapter 7, Unit7 1, 10.1002/0471142735.im0701s85 (2009). 46.BrusselASonigoPAnalysis of early human" exact="immunodeficiency" post="virus type 1 DNA synthesis by use of a"/>
 <result pre="Unit7 1, 10.1002/0471142735.im0701s85 (2009). 46.BrusselASonigoPAnalysis of early human immunodeficiency virus" exact="type 1" post="DNA synthesis by use of a new sensitive assay"/>
 <result pre="Groitl, P., Dobner, T. &amp;amp; Schreiner, S. Human Adenovirus Core" exact="Protein" post="V Is Targeted by the Host SUMOylation Machinery To"/>
 <result pre="V Is Targeted by the Host SUMOylation Machinery To Limit" exact="Essential" post="Viral Functions. J Virol, 92, 10.1128/JVI.01451-17 (2018)."/>
 <result pre="Is Targeted by the Host SUMOylation Machinery To Limit Essential" exact="Viral" post="Functions. J Virol, 92, 10.1128/JVI.01451-17 (2018)."/>
</results>
